Invention Grant
- Patent Title: Afucosylated anti-FGFR2IIIB antibodies
-
Application No.: US16181784Application Date: 2018-11-06
-
Publication No.: US11235059B2Publication Date: 2022-02-01
- Inventor: Thomas Harding , Kristen Pierce , Namrata Patil , Thomas Brennan , Julie Hambleton
- Applicant: Five Prime Therapeutics, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Five Prime Therapeutics, Inc.
- Current Assignee: Five Prime Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: McNeill Baur PLLC
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K39/00 ; A61K33/243 ; A61K31/337 ; A61K31/513 ; A61K45/06
Abstract:
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Public/Granted literature
- US20190175730A1 Afucosylated Anti-FGFR2IIIB Antibodies Public/Granted day:2019-06-13
Information query
